Supplementary Information

Isoxazolopyrimidine-based inhibitors of

Plasmodium falciparum dihydroorotate dehydrogenase with antimalarial activity

Sreekanth Kokkonda¹, Farah El Mazouni², Karen L. White³, John White¹, David M. Shackleford³, Maria Jose Lafuente-Monasterio⁴, Paul Rowland⁴, Krishne Manjalanagara⁵, Jayan T. Joseph⁵, Adolfo Garcia-Pérez⁴, Jorge Fernandez⁴, Francisco Javier Gamo⁴, David Waterson⁶, Jeremy N. Burrows⁶, Michael J. Palmer⁶, Susan A. Charman³, Pradipsinh K. Rathod¹ and Margaret A. Phillips^{2*}

¹Departments of Chemistry and Global Health, University of Washington, Seattle, WA, 98195, USA; ²Department of Biochemistry, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd, Dallas, Texas, 75390-9038, USA; ³Centre for Drug Candidate Optimisation, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC 3052, Australia, ⁴GSK, Tres Cantos Medicines Development Campus, Severo Ochoa, Madrid, 28760, Spain, ⁵Syngene International Ltd, Bangalore, 560 099, India; ⁶Medicines for Malaria Venture, 20, Route de Pré-Bois, 1215 Geneva, Switzerland.

*Author to whom all correspondence should be addressed.

Table of Contents

Supplementary Table S1. X-ray data collection and refinement statistics for *Pf*DHODH bound to **15**Supplementary Figure S1. Electron density difference maps for the **15** binding site on *Pf*DHODH

Supplementary Table S1. X-ray data collection and refinement statistics for compound 15.

| Data collection | |
|----------------------------------|---------------------------|
| Beam line/detector | ESRF ID23-1/ADSC Q315 |
| Resolution (Å) | 163-1.99 (2.29-1.99) |
| Observations | 137823 (6539) |
| Unique reflections | 35930 (1795) |
| Completeness (spherical) (%) | 46.8 (6.7) |
| Completeness (ellipsoidal) (%) | 90.2 (58.0) |
| Multiplicity | 3.8 (3.6) |
| Mean I/ơI | 11.3 (2.0) |
| R _{merge} | 0.088 (0.631) |
| CC _{1/2} | 0.997 (0.709) |
| Refinement | |
| Resolution (Å) | 21.8-1.99 (2.05-1.99) |
| Reflections | 35879 (18) |
| R_{work}/R_{free} | 0.163/0.206 (0.255/0.103) |
| Total number of atoms | 6488 |
| Protein atoms | 5891 |
| Ligand atoms | 128 |
| Waters | 469 |
| Average B-factors (Ų) | |
| Protein (main chain/side chain) | 43.1/52.2 |
| Ligand atoms | 37.9 |
| Waters | 41.4 |
| RMS deviations from ideal values | |
| Bond lengths (Å) | 0.010 |
| Bond angles (°) | 1.18 |

Values for the highest resolution shell are given in parentheses Preliminary structure refinement was carried out at 2.65 Å, where data completeness was 98.5% overall (98.7% for 2.70-2.65 Å).

Supplementary Figure S1. Electron density difference maps in the 15 binding sites. Initial F_o - F_c electron density maps contoured at 3σ (green) and -3σ (red) superposed on the refined protein-inhibitor complex structure. Maps calculated after preliminary refinement of an unliganded protein model against the structure factors of the protein-inhibitor complex. Maps are shown for both subunits A and B observed in the asymmetric unit.



